

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

VEGFA Polyclonal Antibody

Catalog Number:E-AB-93160



Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description	
Reactivity	Human,Mouse,Rat
Immunogen	Recombinant fusion protein of human VEGFA
Host	Rabbit
Isotype	IgG
Purification	Affinity purification
Conjugation	Unconjugated
Formulation	PBS with 0.01% thiomersal, 50% glycerol, pH7.3.
Applications	Recommended Dilution
WB	1:500-1:2000
IF	1:50-1:100
Data	



Western blot analysis of extracts of various cell lines using VEGFA Polyclonal Antibody at 1:1000 dilution. Observed Mw:35KDa Calculated Mw:15-27kDa/34-45kDa



Immunofluorescence analysis of NIH/3T3 using VEGFA Polyclonal Antibody at dilution of 1:100. Blue: DAPI for nuclear staining.

Preparation & Storage

Storage

Store at -20°C. Avoid freeze/thaw cycles.

Background

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

For Research Use Only

A Reliable Research Partner in Life Science and Medicine